Cedarburg acquires Hauser Pharmaceutical Services

Cedarburg Pharmaceuticals, a provider of active pharmaceutical ingredients and key intermediates for the pharmaceutical and biopharmaceutical industries, has acquired InB: Hauser Pharmaceutical Services, a contract development manufacturing organization.

The acquisition is believed to strengthen Cedarburg’s position in the contract development manufacturing organization market and leverages the synergistic capabilities of both companies to offer clients a more fully-integrated manufacturing platform focused on helping clients move new chemical entities to market.

According to Cedarburg, the newly formed company called Cedarburg Hauser Pharmaceuticals will offer customers a broad range of pharmaceutical services to meet the development and production needs of its clients.

Anthony Laughrey, president and CEO of Cedarburg, said: The acquisition allows us to maximize the true potential of both organizations as one fully integrated contract development and manufacturing organization building value for our shareholders, employees, and customers. The merger will also speed up the development and manufacturing of products currently in our product pipeline.

The new Cedarburg Hauser is well positioned to provide increased efficiency for our clients as they move their critical process development and manufacturing projects through clinical development and ultimately into the commercial arena.

Cedarburg Pharmaceuticals is a commercial and clinical API provider. Cedarburg   applies its expertise in process development, validation, Scale-Up and analytical method development.

Hauser is a contract development manufacturing organization dedicated to providing actives and key intermediates to the pharmaceutical and biopharmaceutical industries.